Literature DB >> 2033119

DNA analysis of HLA-DR4B1 subtypes in multiple sclerosis by specific oligonucleotide probes.

M Victoria-Gutierrez1, E Martinez-Naves, E Coto, O Dominguez, F Uría, J M Urra, C López-Larrea.   

Abstract

Conversely to the well-established association of DR2/Dw2 with multiple sclerosis (MS) susceptibility in Caucasoids, several studies have found an association of DR4 in populations from Mediterranean origin. We have studied the distribution of the different DR4B1 subtypes in Spanish MS patients. Oligonucleotide probes were selected in order to type samples amplified by polymerase chain reaction (PCR) from Spanish DR4+ MS patients (25) and controls (28). No DR4B1 subtypes were found to be increased in MS. MS susceptibility linked to DR4 may be due to the presence of shared functional epitopes common to the different HLA-DR4B1 subtypes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2033119     DOI: 10.1016/0165-5728(91)90198-g

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  3 in total

1.  Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire.

Authors:  P A Muraro; M Vergelli; M Kalbus; D E Banks; J W Nagle; L R Tranquill; G T Nepom; W E Biddison; H F McFarland; R Martin
Journal:  J Clin Invest       Date:  1997-07-15       Impact factor: 14.808

2.  HLA class II susceptibility and resistance genes in patients with multiple sclerosis from northern Spain, by DNA-RFLP genotyping.

Authors:  D F Uría; V Gutierrez; B B Menes; J M Arribas; C Lopez-Larrea
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-06       Impact factor: 10.154

3.  Increase of HLA-DRB1*0408 and -DQB1*0301 in HLA-B27 positive reactive arthritis.

Authors:  J Tuokko; H Reijonen; J Ilonen; K Anttila; S Nikkari; T Möttönen; U Yli-Kerttula; A Toivanen
Journal:  Ann Rheum Dis       Date:  1997-01       Impact factor: 19.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.